Nationwide project for animal-free biomedical research on osteoarthritis launched

There are several reasons why there is no medication for osteoarthritis. “Many people describe osteoarthritis as a wear-and-tear disease,” Tim explains. “With that mindset, the focus shifts more towards replacing joints than on halting or preventing the disease. That reduces motivation to develop drugs. In addition, there are many differences between patients, for example in terms of age or stage of the disease. Another reason for the lack of medication is that many drugs pass early animal testing stages but often fail in human clinical trials. Animal models are often poor predictors of how a treatment will work in people, because a rat or mouse simply is not a human. That is why we need new models, developed using cells from our target group: humans.”

The aim of the Ombion project is to realise such models based on human cells. “The models should be representative of a number of aspects that are important in a joint,’ Tim explains. "Pain is one such aspect, as it is often the primary concern of patients. We also look at cartilage, the joint membrane and the lymphatic system. By combining models, we can mimic disease processes in a joint on a laboratory scale. We do this partly in the lab at UM, partly at UMC Utrecht and partly at Utrecht University. We also have support from ReumaNederland, a co-financing partner in this project. The best models will eventually be implemented in physical Ombion labs, which will serve as a centre of expertise where academics and industry partners can access these models.”

The project will span ten years in total. “We hope during this time to be able to accelerate the development of osteoarthritis medication by building models that are better at predicting than those based on animal testing,” Tim says. “That would not only make the results more applicable to humans, but also reduce the need for laboratory animals. The ultimate goal is to make and validate the models in a way that regulatory agencies start accepting such data as preclinical evidence before going to a clinical trial. This spring, the Food and Drug Administration (FDA) in the United States announced its intention to phase out animal experiments for drug development by reducing, refining or replacing them with non-animal methods in their regulations. So the timing of this project is actually quite nice."

Tim is excited that the project has officially begun. “A huge motivator for me is the chance to make a real difference for osteoarthritis patients and to move towards more animal-free research,” he says. “I also find it incredibly motivating to be able to work with so many amazing people in our beautiful consortium with our industry partners, academics and ReumaNederland. Within the UM, we are part of CAPHRI and within Maastricht UMC+ we are part of the Centre for Movement, where osteoarthritis is our key focus. With its focus on prevention, this Ombion project fits incredibly well with CAPHRI and the Centre of Movement. To raise awareness and train the new generation of scientists in the new models being developed, educational activities with global reach are linked to the project activities through Ombion. In this way, we ensure that we link research, education and care."

Text: Joëlle van Wissen
Photo: Thijs Rooimans

Did you enjoy reading this article? Follow us on Instagram and LinkedIn for more.